PSMA-targeting radioligands modified with these entities showed enhanced blood circulation in comparison to [177Lu]Lu-PSMA-617 and, as a consequence, considerably increased accumulation in the tumor tissue, which correlated with better therapeutic outcomes in preclinical settings [10,11,12]. This evidence concerns the gene FOLH1 and neoplasm.